$295.00
-1.5%Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Last Annual Value
25.12B
3-Year CAGR
11%
5-Year CAGR
12%
10-Year CAGR
10%
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Stryker Corporation NYSE:SYK | 25.12B | 7.0% | 8.0% | 8.3% | |
![]() Boston Scientific Corporation NYSE:BSX | 20.07B | 12.1% | 11.0% | 9.1% | |
![]() Medtronic plc NYSE:MDT | 33.54B | 2.4% | 2.2% | 1.5% | |
![]() Pfizer Inc. NYSE:PFE | 62.58B | 1.7% | -5.1% | 1.7% | |
![]() Danaher Corporation NYSE:DHR | 24.57B | 0.9% | -3.6% | 3.8% | |
![]() Amgen Inc. NASDAQ:AMGN | 36.74B | 9.2% | 7.2% | 4.8% | |
![]() Vertex Pharmaceuticals Incorporated NASDAQ:VRTX | 12.07B | 7.0% | 9.8% | 21.6% | |
![]() McKesson Corporation NYSE:MCK | 403.43B | 13.4% | 11.1% | 7.8% | |
![]() Gilead Sciences, Inc. NASDAQ:GILD | 29.44B | 2.8% | 1.5% | -0.3% | |
![]() HCA Healthcare, Inc. NYSE:HCA | 75.60B | 5.2% | 5.2% | 6.2% |
Continue your SYK research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.